Gastric Sleeve Magnetic Implant

Information

  • Research Project
  • 7998327
  • ApplicationId
    7998327
  • Core Project Number
    R43DK083889
  • Full Project Number
    1R43DK083889-01A2
  • Serial Number
    83889
  • FOA Number
    PA-07-435
  • Sub Project Id
  • Project Start Date
    9/30/2010 - 14 years ago
  • Project End Date
    8/31/2012 - 12 years ago
  • Program Officer Name
    DENSMORE, CHRISTINE L
  • Budget Start Date
    9/30/2010 - 14 years ago
  • Budget End Date
    8/31/2012 - 12 years ago
  • Fiscal Year
    2010
  • Support Year
    1
  • Suffix
    A2
  • Award Notice Date
    9/29/2010 - 14 years ago
Organizations

Gastric Sleeve Magnetic Implant

DESCRIPTION (provided by applicant): The occurrence of obesity is increasingly growing, and it has been projected that 40% of the US population will be obese by the year 2025. The World Health Organization estimates over 1.6 billion adults (age 15+) are overweight, and at least 400 million are considered obese. In response, there has been increasing interest in the surgical treatment of morbid obesity with the application of laparoscopic techniques. Our major objective is to establish the safety and efficacy of a Vertical Sleeve Gastrectomy, VSG-like device referred to as the gastric sleeve implant (GSI). The major advantage of GSI is that it does not require gastrectomy and hence leaves the anatomy and physiology of the stomach intact. Furthermore, the implant is reversible and can be removed if desired by the patient and physician. In phase I of this SBIR, we will focus on the validation of the GSI in an in vivo dog model. Therefore, our specific aim is to evaluate the safety and efficacy of a reversible GSI for weight loss in a group of dogs. The device is designed to be implanted laparoscopically, and to be readily removed after implantation if desired, leaving the patient's anatomy healthy, intact, and physiologically normal. The net result of the GSI procedure is a vertical sleeve, or banana-shaped, food track, which is a fraction of the size of the original stomach. The stomach tissue excluded from the food track remains healthy and unharmed, but the digestive volume is restricted to limit the patient's food intake. The GSI mimics the benefits of the increasingly popular VSG, but it inherently avoids some of the shortcomings of the VSG and other commonly used bariatric procedures. These current procedures all suffer from one or more of the following shortcomings: 1) Leaks and complications, especially from staple lines;2) Nutritional deficiencies from malabsortive therapies;3) Frequent follow-up appointments for adjustments;and 4) Insufficient and/or unsustained weight loss amongst others. The design of the proposed GSI and our preliminary data address some of these shortcomings. PUBLIC HEALTH RELEVANCE: The major objective of this proposal is to establish the safety and efficacy of an implant bariatric device. The major advantage of this weight loss device is that it does not require excision and removal of the stomach and hence leaves the anatomy and physiology of the stomach intact. Furthermore, the implant is reversible and can be removed if desired by the patient and physician leaving the stomach healthy and intact.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    99936
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:99936\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    3DT HOLDINGS, LLC
  • Organization Department
  • Organization DUNS
    804419740
  • Organization City
    INDIANAPOLIS
  • Organization State
    IN
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    462041927
  • Organization District
    UNITED STATES